Genomics raises £35m from F-Prime Capital and Foresight Partners to advance preventative healthcare tools.
The funding round was led by F-Prime Capital and Foresight Partners to support risk estimation technology and workforce expansion.
Share allotment filed at Companies House
Oxford-based Genomics develops proprietary genetic algorithms to generate population-wide health risk assessments and advance preventative healthcare.
Genomics has secured £35m in a funding round led by F-Prime Capital and Foresight Partners, with participation from Infinity Investment Partners and MassMutual.
The Oxford-based business plans to allocate the capital towards developing its risk estimation technology aimed at preventing common diseases and cancers, alongside supporting workforce expansion as it works towards profitability.
The latest financing follows a $30m round raised in 2021 by the university spinout, which employs a team of over 100 people across the UK and the US.
From the founder
"Our vision is that in 10 to 15 years, genetic information will be ubiquitous in healthcare systems"
Peter Donnelly
CEO at Genomics
Use of funds
- 01Continue product development
- 02Grow the team
